Catalyst stock: buy or sell?
February 26th, 2020
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies for people with rare debilitating diseases.
Should I buy Catalyst stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to choose your own trading strategy that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Only 1 of our buy setups matches with Catalyst stock now:
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||Yes|
|100d MA crossing up 200d MA||No|
Is Catalyst stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.Unfortunately, we couldn't find any rating for CPRX stock for the last 30 days.
Catalyst stock analysis
After sliding a bloodcurdling -8.39% yesterday, Catalyst closed today at $4.66 and jumped a remarkable 2.87%.
After sliding a bloodcurdling -8.39% yesterday, Catalyst closed today at $4.66 and jumped a remarkable 2.87%. Since price and SMA200d lines crossed up today, CPRX climbed $0.13 (2.87%). From a daily perspective, CPRX is in a short term uptrend after plotting its last bottom ($4.36, on February/7) higher than the previous bottom, and its last top ($5.28, on Thursday) also over the previous top. Now trading in between its last bottom and last top CPRX might consolidate in a plain range, waiting to break out over $5.28 or down under $4.36.
After boosting an amazing 8.45% in a week last week, Catalyst Pharmaceuticals closed this week at $4.66 and plummed a spooky -10.56%. This week broke a green streak of 4 weeks.
Far behind is the all-time high Catalyst recorded early September and since then the price is -39.24% below that top. Catalyst stock is trading in the range of its last top and last bottom. Loosing would mean breaking the current uptrend. Breakdowns under last bottom are selling point signals for some trading strategies.
Catalyst stock price history
Catalyst IPO was on November 8th, 2006 at $6.00 per share1. Since then, CPRX stock lost a -22.30%, with a yearly average of -1.70%.
1: Adjusted price after possible price splits or reverse-splits.
Catalyst stock historical price chart
CPRX stock reached all-time highs on September with a price of $7.67.
Catalyst stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' CPRX stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not found any price forecast for Catalyst stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, Catalyst Pharmaceuticals reported its latest financial data, posting a shining growth for the Earnings per Share (EPS) ratio. Experts were expecting $-0.12 per share, but Catalyst Pharmaceuticals posted $-0.14.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to , last anual revenues report draw of to $0.50 million USD. When comparing 2018 vs , , profit margin (that is, the net income divided by revenues) a to -6,800.70%.
|2018||$0.50 M||-||$-34.00 M-6800.7%||-|
Quarterly financial resultsCatalyst posted $0.50 M in revenues for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter earnings marked $-14.50 M with a profit margin of -2,899.92%. Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Catalyst Pharmaceuticals sales marked an extraordinary growth and boosted a inf%.
|2018-Q4||$0.50 M||-||$-14.50 M-2899.9%||-|
Catalyst ownershipWhen you are planning to invest in shares of a company, it's worth to overview its ownership structure.
Catalyst Pharmaceuticals shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 6.92% of all shares.
In case of Catalyst Pharmaceuticals stock, 63.25% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CPRX stock account 0.00%, no big difference from last month.
The following table compares ownership indicators for other stocks related to Catalyst:
|Market cap||$480.2 M|
|Total shares||103.1 M|
|Float shares||95.9 M|
|- Institutional holdings (%)||63.2%|
|- Insider holdings (%)||6.9%|
|Shares in short selling||0.0%|
|Wednesday, February 26th, 2020|
|Day range||$4.44 - $4.80|
|Average true range||$0.29|
|50d mov avg||$4.33|
|100d mov avg||$4.57|
|200d mov avg||$4.65|
Catalyst performanceTo measure stock performance is always good to benchmark with competitors or related stocks. We picked as the bechmarking frame for Catalyst stock.